Sue Stansfield

Director of Clinical Trial Programme

Sue is Director of Clinical Trials at COMPASS, leading the global clinical trials programme.

Sue gained her PhD in neuroendocrinology in the 1980s and began her career at Wellcome Research Labs, working on the successful registration of Lamictal®. She moved onto Janssen and Parke-Davies in increasingly senior roles in CNS drug development (anxiety, depression, epilepsy, Alzheimer’s Disease). In 1991, Sue joined Quintiles as the Global Project Director leading the development of a reversible inhibitor of monoamine oxidase A (RIMA) towards an NDA (US new drug application) in panic disorder and social phobia with line extension outside USA. From there, Sue pursued a career in the Clinical Research Organisation (CRO) industry that spanned 25 years. She has worked for a number of leading CROs including Quintiles (now IQVIA) PPD, PRA, Premier Research and inVentiv Health (now Syneos Health), successively expanding her remit with additional functions and regions. At COMPASS Pathways, Sue combines her scientific experience with her trial execution expertise to develop and lead the clinical trials programme.

It is so refreshing to work in such a dynamic team with one single agenda; to overcome the barriers in order to benefit patients.